1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+)

This is an abbreviated version, for detailed information about 15-hydroxyprostaglandin dehydrogenase (NAD+), go to the full flat file.

Reaction

(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate
+
NAD+
=
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate
+
NADH
+
H+

Synonyms

11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase, 15-hydroxy prostaglandin dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 15-hydroxyprostanoic dehydrogenase, 15-OH-PGDH, 15-PGDH, 15-prostaglandin dehydrogenase, dehydrogenase, 15-hydroxyprostaglandin, HPGD, NAD+ dependent 15-hydroxyprostaglandin dehydrogenase, NAD+ dependent PGDH, NAD+-15-hydroxy prostanoate oxidoreductase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I), NAD+-dependent 15-PGDH, NAD+-linked 15-hydroxyprostaglandin dehydrogenase, NAD-dependent 15-hydroxyprostaglandin dehydrogenase, NAD-specific 15-hydroxyprostaglandin dehydrogenase, PGDH, prostaglandin dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)

Activating Compound

Activating Compound on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
17beta-estradiol
-
slight activation
corticosterone
-
4fold activation
cortisone
-
5fold activation
cyclooxygenase-1 inhibitors
-
selective or not
-
dexamethasone
-
10fold activation
dihydrotestosterone
-
-
erlotinib
-
epidermal growth factor receptor tyrosine kinase inhibitor, trreatment of cells increases the expression of the enzyme in a subset of non-small-cell lung cancer lines
estradiol
-
2fold activation
pioglitazone
-
upregulation of expression, involving peroxisome proliferator-activated receptor gamma. Upregulation results in reduced production of prostaglandin E2 and finally inhibition of lung cancer growth
Prednisolone
-
6fold activation
progesterone
rosiglitazone
-
upregulation of expression, involving peroxisome proliferator-activated receptor gamma. Upregulation results in reduced production of prostaglandin E2 and finally inhibition of lung cancer growth
sulindac sulfone
-
-
testosterone
Thionicotinamide adenine dinucleotide
Triamcinolone
-
7fold activation
additional information
-